KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
Europe • Frankfurt Stock Exchange • FRA:PHI1 • NL0000009538
24.36 EUR
+0.21 (+0.87%)
Last: Feb 2, 2026, 07:00 PM
Overall PHI1 gets a fundamental rating of 3 out of 10. We evaluated PHI1 against 68 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year PHI1 was profitable.
- In the past year PHI1 had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
- PHI1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- PHI1's Return On Assets of 0.63% is on the low side compared to the rest of the industry. PHI1 is outperformed by 63.24% of its industry peers.
- With a Return On Equity value of 1.56%, PHI1 is not doing good in the industry: 63.24% of the companies in the same industry are doing better.
- Looking at the Return On Invested Capital, with a value of 3.95%, PHI1 is doing worse than 64.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.63% | ||
| ROE | 1.56% | ||
| ROIC | 3.95% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 0.93%, PHI1 is doing worse than 63.24% of the companies in the same industry.
- PHI1 has a worse Operating Margin (6.10%) than 60.29% of its industry peers.
- In the last couple of years the Operating Margin of PHI1 has declined.
- PHI1's Gross Margin of 43.49% is on the low side compared to the rest of the industry. PHI1 is outperformed by 73.53% of its industry peers.
- PHI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.1% | ||
| PM (TTM) | 0.93% | ||
| GM | 43.49% |
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHI1 is destroying value.
- Compared to 1 year ago, PHI1 has less shares outstanding
- The number of shares outstanding for PHI1 has been increased compared to 5 years ago.
- Compared to 1 year ago, PHI1 has a worse debt to assets ratio.
2.2 Solvency
- PHI1 has an Altman-Z score of 1.98. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 1.98, PHI1 is not doing good in the industry: 60.29% of the companies in the same industry are doing better.
- The Debt to FCF ratio of PHI1 is 14.51, which is on the high side as it means it would take PHI1, 14.51 years of fcf income to pay off all of its debts.
- With a Debt to FCF ratio value of 14.51, PHI1 is not doing good in the industry: 63.24% of the companies in the same industry are doing better.
- A Debt/Equity ratio of 0.69 indicates that PHI1 is somewhat dependend on debt financing.
- PHI1's Debt to Equity ratio of 0.69 is on the low side compared to the rest of the industry. PHI1 is outperformed by 72.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 14.51 | ||
| Altman-Z | 1.98 |
ROIC/WACC0.6
WACC6.62%
2.3 Liquidity
- PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of PHI1 (1.32) is worse than 61.76% of its industry peers.
- A Quick Ratio of 0.86 indicates that PHI1 may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.86, PHI1 is doing worse than 67.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.32 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
- PHI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.15%, which is quite good.
- PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.17% yearly.
- PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -1.43%.
- The Revenue has been growing slightly by 1.00% on average over the past years.
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
3.2 Future
- The Earnings Per Share is expected to grow by 10.28% on average over the next years. This is quite good.
- Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.00% on average per year.
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 16.46, the valuation of PHI1 can be described as correct.
- PHI1's Price/Earnings ratio is rather cheap when compared to the industry. PHI1 is cheaper than 94.12% of the companies in the same industry.
- When comparing the Price/Earnings ratio of PHI1 to the average of the S&P500 Index (28.41), we can say PHI1 is valued slightly cheaper.
- Based on the Price/Forward Earnings ratio of 16.01, the valuation of PHI1 can be described as correct.
- 72.06% of the companies in the same industry are more expensive than PHI1, based on the Price/Forward Earnings ratio.
- PHI1's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.64.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.46 | ||
| Fwd PE | 16.01 |
4.2 Price Multiples
- 69.12% of the companies in the same industry are more expensive than PHI1, based on the Enterprise Value to EBITDA ratio.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHI1 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 40.58 | ||
| EV/EBITDA | 12.87 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)3.33
PEG (5Y)N/A
EPS Next 2Y4.81%
EPS Next 3Y7.44%
5. Dividend
5.1 Amount
- PHI1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:PHI1 (2/2/2026, 7:00:00 PM)
24.36
+0.21 (+0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/bmo
Earnings (Next)02-10 2026-02-10/amc
Inst Owners44.83%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap23.46B
Revenue(TTM)17.78B
Net Income(TTM)165.00M
Analysts72.14
Price Target27.07 (11.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP199.39%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.57%
Min EPS beat(2)14.1%
Max EPS beat(2)31.04%
EPS beat(4)3
Avg EPS beat(4)13.85%
Min EPS beat(4)-11.97%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-0.89%
EPS beat(12)6
Avg EPS beat(12)18.79%
EPS beat(16)6
Avg EPS beat(16)4.51%
Revenue beat(2)0
Avg Revenue beat(2)-2.19%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-1.97%
Revenue beat(4)0
Avg Revenue beat(4)-2.34%
Min Revenue beat(4)-3.04%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.43%
Revenue beat(12)2
Avg Revenue beat(12)-1.64%
Revenue beat(16)2
Avg Revenue beat(16)-1.76%
PT rev (1m)-2.2%
PT rev (3m)-1.72%
EPS NQ rev (1m)1.37%
EPS NQ rev (3m)5.07%
EPS NY rev (1m)0.57%
EPS NY rev (3m)4.51%
Revenue NQ rev (1m)-0.52%
Revenue NQ rev (3m)-0.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.46 | ||
| Fwd PE | 16.01 | ||
| P/S | 1.32 | ||
| P/FCF | 40.58 | ||
| P/OCF | 19.12 | ||
| P/B | 2.22 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.87 |
EPS(TTM)1.48
EY6.08%
EPS(NY)1.52
Fwd EY6.25%
FCF(TTM)0.6
FCFY2.46%
OCF(TTM)1.27
OCFY5.23%
SpS18.47
BVpS10.96
TBVpS-1.42
PEG (NY)3.33
PEG (5Y)N/A
Graham Number19.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.63% | ||
| ROE | 1.56% | ||
| ROCE | 5.61% | ||
| ROIC | 3.95% | ||
| ROICexc | 3.95% | ||
| ROICexgc | 10.33% | ||
| OM | 6.1% | ||
| PM (TTM) | 0.93% | ||
| GM | 43.49% | ||
| FCFM | 3.25% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 14.51 | ||
| Debt/EBITDA | 2.93 | ||
| Cap/Depr | 46.69% | ||
| Cap/Sales | 3.65% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 49.6% | ||
| Profit Quality | 350.3% | ||
| Current Ratio | 1.32 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | 1.98 |
F-ScoreN/A
WACC6.62%
ROIC/WACC0.6
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
EPS Next Y4.94%
EPS Next 2Y4.81%
EPS Next 3Y7.44%
EPS Next 5Y10.28%
Revenue 1Y (TTM)-1.43%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3%
EBIT growth 1Y712.43%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.95%
EBIT Next 3Y19.49%
EBIT Next 5Y15.13%
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%
KONINKLIJKE PHILIPS NV / PHI1.DE FAQ
What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.
What is the valuation status for PHI1 stock?
ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.
How profitable is KONINKLIJKE PHILIPS NV (PHI1.DE) stock?
KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.
How financially healthy is KONINKLIJKE PHILIPS NV?
The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.
Can you provide the dividend sustainability for PHI1 stock?
The dividend rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 0 / 10 and the dividend payout ratio is 199.39%.